Tesamorelin: Targeting Visceral Fat in HIV-Associated Lipodystrophy

Tesamorelin: Targeting Visceral Fat in HIV-Associated Lipodystrophy HIV-associated lipodystrophy is a complex metabolic syndrome characterized by abnormal body fat distribution, including visceral adiposity (excess fat around internal organs) and subcutaneous fat loss. This condition is often linked to antiretroviral therapies and can lead to increased risk of cardiovascular disease and insulin resistance. There's a significant need for treatments that can specifically reduce visceral fat without compromising other fat stores. This digest summarizes the known clinical profile of Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog, which addresses the visceral adiposity component of HIV-associated lipodystrophy.

Clinical trials have consistently demonstrated that Tesamorelin significantly reduces visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy. > In pivotal studies, patients treated with Tesamorelin experienced a 15-18% mean reduction in VAT from baseline, compared to a 0-5% increase or no change in the placebo group (p<0.001). This reduction was sustained over 26 weeks and was associated with improvements in other metabolic markers. For instance, triglyceride levels showed a 10-15% decrease in the Tesamorelin group versus placebo (p<0.05), and cholesterol ratios also improved. The treatment did not significantly impact subcutaneous fat, highlighting its specific action on visceral fat.